STML - Stemline Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
6.83
-0.27 (-3.80%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close7.10
Open7.06
Bid6.80 x 1300
Ask7.01 x 3000
Day's Range6.81 - 7.11
52 Week Range6.01 - 18.22
Volume417,666
Avg. Volume761,155
Market Cap337.414M
Beta (5Y Monthly)1.49
PE Ratio (TTM)N/A
EPS (TTM)-2.28
Earnings DateMar 15, 2020 - Mar 19, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.50
  • STEMLINE THERAPEUTICS, INC. INVESTIGATION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Stemline Therapeutics, Inc.
    PR Newswire

    STEMLINE THERAPEUTICS, INC. INVESTIGATION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Stemline Therapeutics, Inc.

    Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of shareholders of Stemline Therapeutics, Inc. (Nasdaq: STML) ("Stemline" or the "Company") resulting from allegations that Stemline Therapeutics, Inc. and/or its executives may have issued materially misleading information to the investing public.

  • We're Hopeful That Stemline Therapeutics (NASDAQ:STML) Will Use Its Cash Wisely
    Simply Wall St.

    We're Hopeful That Stemline Therapeutics (NASDAQ:STML) Will Use Its Cash Wisely

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • Benzinga

    The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug

    The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 13.) Arvinas Inc (NASDAQ: ARVN ) Baxter International ...

  • GlobeNewswire

    Stemline Therapeutics Announces Preliminary 2019 Net Revenues for ELZONRIS® (tagraxofusp) and Highlights Commercial and Clinical Growth Drivers

    Stemline Therapeutics, Inc. (STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced preliminary net revenues for 2019, as well as outlined key BPDCN market successes and upcoming commercial and clinical milestones. The above financial information is based on preliminary unaudited information, is subject to adjustment, and does not present all information necessary for an understanding of the Company’s full-year and fourth quarter financial results for 2019. Stemline expects to report complete audited 2019 financial results on or before March 16, 2020.

  • GlobeNewswire

    Stemline Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    NEW YORK, Jan. 08, 2020 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel.

  • Street Watch: Top Analysts Make Moves on 3 Buy-Rated Stocks
    TipRanks

    Street Watch: Top Analysts Make Moves on 3 Buy-Rated Stocks

    Onward and upward the market goes, with December providing further cheer as new record highs for the S&P 500 were notched in the last week. Giddy from 2019’s riches and ready to bring in the New Year, the optimism on the Street, following a brief slump, has been renewed.While analysts are divided as to whether the next year can follow this one’s record breaking run, one thing looks certain; investors will still be on the lookout for the right addition to their portfolio.TipRanks - a company that tracks and measures the performance of analysts - has an instrument that comes in handy here. The Daily Stock Ratings tool allows a user to see what stocks are hot and, yes, what stocks are not. Analysts’ ratings and their performances are displayed, too, further helping the intrepid investor make the right decision.Let’s have a look, then, at 3 Buy-rated stocks a number of the Street’s leading analysts recently pulled the trigger on.Stemline Therapeutics Inc (STML)With a focus on developing and bringing to market novel oncology therapies, Stemline Therapeutics has recently been turning heads on the Street.The New York based biotech has several therapies in the pipeline, but already has one on the market. Elzonris is used to treat a rare blood cancer called blastic plasmacytoid dendritic cell neoplasm (BPDCN), and was approved by the FDA in December 2018 for the treatment of adults and pediatric patients over 2 years old. The drug is currently in clinical trials to assess further indications.Cantor Fitzgerald’s Alethia Young calls Elzonris a "pipeline in a product" and believes the biotech is undervalued. Stemline’s market cap is currently $555.4 million, and Young expects sales from Elzonris for BPDCN (sans maintenance therapy) to be in the region of $150 million by 2025. We’re talking about just the US here. Furthermore, the 5-star analyst thinks the possible expansion of Elzonris into the BPDCN maintenance setting in 2021 could, by 2029, result in US sales of $223M. Young maintains that as "as investors take notice of progress in the label expansion opportunities”, the next 12 months should see Stemline’s share price take off.Accordingly, Young initiated coverage on Stemline with an Overweight rating and set a price target of $18. This implies upside potential of 62% over the next 12 months. (To watch Young’s track record, click here)The Cantor analyst’s bullish thesis is mirrored by that of the Street’s. All 5 analysts tracked over the last three months rate the stock a Buy, and therefore, Stemline has a Strong Buy consensus rating. An average price target of $22.75 outstrips Young’s target and indicates gains of 105% could be in the cards. (See Stemline stock analysis on TipRanks) X4 Pharmaceuticals Inc (XFOR)The biotech sector’s recent upturn in the market hasn’t, unfortunately, had any effect on X4 Pharmaceuticals. The rare disease focused biotech has had a rough year in the market, and its share price is down by 21% year-to-date. The word on the Street, though, is that this is all about to change.The company has several drugs in the pipeline, but its lead candidate is mavorixafor (X4P-001), currently in Phase 3 development for the treatment of WHIM syndrome. The rare, inherited condition is an immunodeficiency disease caused by genetic mutations in the CXCR4 receptor gene. Designated orphan status by the FDA in 2018, the drug is also in development for several other conditions, including Waldenström’s macroglobulinemia (WM).Roth Capital’s Zegbeh Jallah highlights XFOR’s “well experienced team” which includes Dr. Renato Skerlj, who developed the first CXCR4 antagonist (plerixafor), as making it a stand-out. Jallah also bases his bullish thesis on a “strong conviction around the clinical and commercial outlook” of mavorixafor, and “a robust pipeline of optimized CXCR4 modulators that could offer improved benefits across a broader range of diseases.” As a result, the analyst initiated coverage of X4 with a Buy rating and a price target of $20, indicating handsome upside potential of 82%. (To watch Jallah’s track record, click here)A fellow analyst praising XFOR is Oppenheimer’s Leland Gershell. The 5-star analyst expects the drug to gain approval for WHIM syndrome and remains "cautiously optimistic" about its part to play in Waldenstrom's macroglobulinemia. Leland initiated coverage with an Outperform rating and a price target of $20, too. (To watch Gershell’s track record, click here)3 other analysts have chipped in with a take on X4 over the last three months and all have reached the same conclusion: Buy. Therefore, the rare disease specialist has a Strong Buy consensus rating. The average price target of $20.25 could provide investors with gains of 84% over the next 12 months. (See X4 Pharmaceuticals stock analysis on TipRanks) See also: 3 “Strong Buy” Energy Stocks with Electric Upside PotentialiMedia Brands Inc (IMBI)Moving on from the biotech industry, we encounter a fellow struggler. Although in a completely different industry, multiplatform commerce company iMedia Brands hasn’t had much joy in 2019, either. Languishing in the doldrums, the company has a year-to-date loss of 7%.That being said, iMedia has an expanding portfolio of shopping television networks and new media businesses including ShopHQ and iMedia Web Services. November saw new additions to the list, too. The first, Float Left Interactive, an OTT (over the top) and TVE (TV everywhere) service provider, has launched a string of OTT apps and counts NBC, Comcast and CBS among its clients. The second, J.W. Hulme, is a maker of leather bags and accessories, and will get its own programming on ShopHQ's cable channel.So, with the new developments in place, is now the right time to get in on iMedia? It is according to D.A. Davidson’s Tom Forte. The 5-star analyst forecasts iMedia revenue to grow by 3% per year over the next three years and projects that by 2022, the company’s EBITDA margin will expand by almost 500 basis points to 3.1%.Furthermore, with LaVenta, the company’s new omni-channel, Spanish language, television shopping network launching in Q1 2020, Forte acknowledges iMedia’s potential for expansion outside the US.To this end, Forte initiated coverage on the interactive media company with a Buy rating, alongside a price target of $10. The bullish target indicates upside potential of a whopping 170%. (To watch Forte’s track record, click here)iMedia currently has only 1 other analyst assessing the company’s 12-month potential, but he happens to be a vocal fan, too. Lake Street’s Mark Argento reckons the next year could see iMedia’s share price reach $15, which lends itself to a massive 305% increase from the current price. (To watch Argento’s track record, click here)Put together, the media company has a Moderate Buy consensus rating and an average price target of $12.50. Potentially, then, investors could be lining their pockets with a 237% gain next year. (See iMedia price targets and analyst ratings on TipRanks)

  • Stemline Therapeutics Inc (STML): Hedge Funds Are Snapping Up
    Insider Monkey

    Stemline Therapeutics Inc (STML): Hedge Funds Are Snapping Up

    Is Stemline Therapeutics Inc (NASDAQ:STML) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to […]

  • GlobeNewswire

    Stemline Therapeutics Recaps ELZONRIS Clinical Data Presentations in Patients with Myelofibrosis (oral presentation) and Multiple Myeloma at the 61st American Society of Hematology (ASH) Annual Meeting

    NEW YORK, Dec. 10, 2019 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel.

  • GlobeNewswire

    Stemline Therapeutics Names Robert M. Francomano Chief Commercial Officer

    NEW YORK, Dec. 06, 2019 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel.

  • GlobeNewswire

    Stemline Therapeutics Highlights Three ELZONRIS Presentations, Including an Oral Presentation in Myelofibrosis, at Upcoming ASH Meeting

    NEW YORK, Dec. 06, 2019 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel.

  • GlobeNewswire

    Stemline Therapeutics to Present at Piper Jaffray’s 31st Annual Healthcare Conference

    NEW YORK, Nov. 29, 2019 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel.

  • Thomson Reuters StreetEvents

    Edited Transcript of STML earnings conference call or presentation 8-Nov-19 1:00pm GMT

    Q3 2019 Stemline Therapeutics Inc Earnings Call

  • TheStreet.com

    Differing Post-Earnings Tales of 2 Small-Cap Underachievers

    Shares of Stemline Therapeutics and Entercom Communications headed opposite directions last Friday after reporting results.

  • Benzinga

    The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut

    The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 7.) Collegium Pharmaceutical Inc (NASDAQ: COLL ...

  • GlobeNewswire

    Stemline Therapeutics Reports Third Quarter 2019 Financial Results

    Net revenue for ELZONRIS® was $13.3 million for the third quarterNew patient starts estimated to have increased greater than 20% from last quarterConference call and live.

  • GlobeNewswire

    Stemline Therapeutics Announces Three ELZONRIS Presentations, Including an Oral Presentation in Myelofibrosis, at Upcoming ASH Meeting

    NEW YORK, Nov. 06, 2019 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel.

  • GlobeNewswire

    Stemline Therapeutics to Host Conference Call on Third Quarter 2019 Financial Results on November 8, 2019

    Stemline Therapeutics, Inc. (STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that the company will host a conference call and webcast on Friday, November 8, 2019 at 8:00 a.m. ET to report its third quarter 2019 financial results and other business highlights. ELZONRIS® (tagraxofusp-erzs), a CD123-directed cytotoxin, is approved by the U.S. Food and Drug Administration (FDA) and commercially available in the U.S. for the treatment of adult and pediatric patients, two years or older, with blastic plasmacytoid dendritic cell neoplasm (BPDCN). In Europe, a marketing authorization application (MAA) is under review by the European Medicines Agency (EMA).

  • Stemline Therapeutics Inc (STML) Is Burning These Hedge Funds
    Insider Monkey

    Stemline Therapeutics Inc (STML) Is Burning These Hedge Funds

    It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]

  • Did Changing Sentiment Drive Stemline Therapeutics's (NASDAQ:STML) Share Price Down By 41%?
    Simply Wall St.

    Did Changing Sentiment Drive Stemline Therapeutics's (NASDAQ:STML) Share Price Down By 41%?

    The simplest way to benefit from a rising market is to buy an index fund. While individual stocks can be big winners...

  • GlobeNewswire

    Stemline Therapeutics Announces ELZONRIS® Clinical Data Selected for Oral Presentation at the 81st Annual Meeting of the Japanese Society of Hematology

    NEW YORK, Oct. 08, 2019 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel.

  • GlobeNewswire

    Stemline Therapeutics Recaps Felezonexor (SL-801) Clinical Data Presentation From ESMO 2019 Congress

    NEW YORK, Oct. 01, 2019 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel.

  • GlobeNewswire

    Stemline Therapeutics Announces Felezonexor (SL-801) Clinical Data to be Featured at Upcoming ESMO 2019 Congress

    NEW YORK, Sept. 27, 2019 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel.

  • GlobeNewswire

    Stemline Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

    NEW YORK, Sept. 26, 2019 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel.

  • Does The Stemline Therapeutics, Inc. (NASDAQ:STML) Share Price Tend To Follow The Market?
    Simply Wall St.

    Does The Stemline Therapeutics, Inc. (NASDAQ:STML) Share Price Tend To Follow The Market?

    If you're interested in Stemline Therapeutics, Inc. (NASDAQ:STML), then you might want to consider its beta (a measure...

  • GlobeNewswire

    Stemline Therapeutics to Present at the Ladenburg Thalmann 2019 Healthcare Conference

    NEW YORK, Sept. 18, 2019 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel.